Bart N Ford1, Robert H Yolken2, Faith B Dickerson3, T Kent Teague4, Michael R Irwin5, Martin P Paulus1, Jonathan Savitz1. 1. Laureate Institute for Brain Research,Tulsa, OK,USA. 2. Stanley Division of Developmental Neurovirology,Johns Hopkins University,Baltimore, MD,USA. 3. Sheppard Pratt Health System,Baltimore, MD,USA. 4. Departments of Surgery and Psychiatry,University of Oklahoma School of Community Medicine,Department of Biochemistry and Microbiology,Oklahoma State University Center for Health Sciences,Tulsa, OK,USA. 5. Cousins Center for Psychoneuroimmunology at UCLA, Semel Institute for Neuroscience and UCLA David Geffen School of Medicine,Los Angeles, CA,USA.
Abstract
BACKGROUND: Depression can impair the immunogenicity of vaccine administration in adults. Whereas many vaccinations are administered in childhood, it is not known whether adolescent or adult onset depression is associated with impairments in the maintenance of protection of childhood vaccines. This study tested the hypothesis that individuals with adolescent or adult onset mood disorders would display compromised immunity to measles, a target of childhood vaccination. METHODS: IgG antibodies to measles were quantified using a solid phase immunoassay in volunteers with bipolar disorder (BD, n = 64, mean age of onset = 16.6 ± 5.6), currently depressed individuals with major depressive disorder (cMDD, n = 85, mean age of onset = 17.9 ± 7.0), remitted individuals with a history of MDD (rMDD, n = 82, mean age of onset = 19.2 ± 8.6), and non-depressed comparison controls (HC, n = 202), all born after the introduction of the measles vaccine in the USA in 1963. RESULTS: Relative to HC, both the cMDD group (p = 0.021, adjusted odds ratios (OR) = 0.47, confidence interval (CI) = 0.24-0.90), and the rMDD group (p = 0.038, adjusted OR = 0.50, CI = 0.26-0.97) were less likely to test seropositive for measles. Compared with unmedicated MDD participants, currently medicated MDD participants had a longer lifetime duration of illness and were less likely to test seropositive for measles. CONCLUSIONS: Individuals with adolescent or adult onset MDD are less likely to test seropositive for measles. Because lower IgG titers are associated with increased risk of measles infection, MDD may increase the risk and severity of infection possibly because of impaired maintenance of vaccine-related protection from measles.
BACKGROUND:Depression can impair the immunogenicity of vaccine administration in adults. Whereas many vaccinations are administered in childhood, it is not known whether adolescent or adult onset depression is associated with impairments in the maintenance of protection of childhood vaccines. This study tested the hypothesis that individuals with adolescent or adult onset mood disorders would display compromised immunity to measles, a target of childhood vaccination. METHODS: IgG antibodies to measles were quantified using a solid phase immunoassay in volunteers with bipolar disorder (BD, n = 64, mean age of onset = 16.6 ± 5.6), currently depressed individuals with major depressive disorder (cMDD, n = 85, mean age of onset = 17.9 ± 7.0), remitted individuals with a history of MDD (rMDD, n = 82, mean age of onset = 19.2 ± 8.6), and non-depressed comparison controls (HC, n = 202), all born after the introduction of the measles vaccine in the USA in 1963. RESULTS: Relative to HC, both the cMDD group (p = 0.021, adjusted odds ratios (OR) = 0.47, confidence interval (CI) = 0.24-0.90), and the rMDD group (p = 0.038, adjusted OR = 0.50, CI = 0.26-0.97) were less likely to test seropositive for measles. Compared with unmedicated MDDparticipants, currently medicated MDDparticipants had a longer lifetime duration of illness and were less likely to test seropositive for measles. CONCLUSIONS: Individuals with adolescent or adult onset MDD are less likely to test seropositive for measles. Because lower IgG titers are associated with increased risk of measlesinfection, MDD may increase the risk and severity of infection possibly because of impaired maintenance of vaccine-related protection from measles.
Entities:
Keywords:
Depression; infection; major depressive disorder; measles; stress; vaccine
Authors: Aric A Prather; Martica Hall; Jacqueline M Fury; Diana C Ross; Matthew F Muldoon; Sheldon Cohen; Anna L Marsland Journal: Sleep Date: 2012-08-01 Impact factor: 5.849
Authors: J K Kiecolt-Glaser; R Glaser; S Gravenstein; W B Malarkey; J Sheridan Journal: Proc Natl Acad Sci U S A Date: 1996-04-02 Impact factor: 11.205
Authors: Konrad Bochennek; Regina Allwinn; Rebecca Langer; Martina Becker; Oliver T Keppler; Thomas Klingebiel; Thomas Lehrnbecher Journal: Vaccine Date: 2014-04-29 Impact factor: 3.641
Authors: Michael R Irwin; Myron J Levin; Carmen Carrillo; Richard Olmstead; Anne Lucko; Nancy Lang; Michael J Caulfield; Adriana Weinberg; Ivan S F Chan; Jim Clair; Jeff G Smith; R D Marchese; Heather M Williams; Danielle J Beck; Patricia T McCook; Gary Johnson; Michael N Oxman Journal: Brain Behav Immun Date: 2011-02-15 Impact factor: 7.217
Authors: N J Kassebaum; A G C Smith; E Bernabé; T D Fleming; A E Reynolds; T Vos; C J L Murray; W Marcenes Journal: J Dent Res Date: 2017-04 Impact factor: 6.116
Authors: Mark A Frye; Brandon J Coombes; Susan L McElroy; Lori Jones-Brando; David J Bond; Marin Veldic; Francisco Romo-Nava; William V Bobo; Balwinder Singh; Colin Colby; Michelle K Skime; Joanna M Biernacka; Robert Yolken Journal: JAMA Psychiatry Date: 2019-12-01 Impact factor: 21.596
Authors: Karren Xiao; Emily S Gillissie; Leanna M W Lui; Felicia Ceban; Kayla M Teopiz; Hartej Gill; Bing Cao; Roger Ho; Joshua D Rosenblat; Roger S McIntyre Journal: J Affect Disord Date: 2022-02-12 Impact factor: 4.839
Authors: Haixia Zheng; Bart N Ford; Maurizio Bergamino; Rayus Kuplicki; Peter W Hunt; Jerzy Bodurka; T Kent Teague; Michael R Irwin; Robert H Yolken; Martin P Paulus; Jonathan Savitz Journal: Mol Psychiatry Date: 2020-11-22 Impact factor: 15.992
Authors: Eva Z Reininghaus; Mirko Manchia; Nina Dalkner; Nina Bonkat; Alessio Squassina; Isabel Hodl; Eduard Vieta; Andreas Reif; Tomas Hajek; Mikael Landén; Christoph U Correll; Jan Scott; Bruno Etain; Marcella Rietschel; Veerle Bergink; Monica Martinez-Cengotitabengoa; Lars Vedel Kessing; Andrea Fagiolini; Michael Bauer; Guy Goodwin; Ana Gonzalez-Pinto; Ralph W Kupka; Thomas G Schulze; Trine V Lagerberg; Ayşegül Yildiz; Chantal Henry; Gunnar Morken; Phillip Ritter; René Ernst Nieslen; Rasmus W Licht; Andreas Bechdolf; Ole A Andreassen; Frederike Tabea Fellendorf Journal: Eur Neuropsychopharmacol Date: 2021-09-10 Impact factor: 4.600